1-(氨甲基)-N,N-二甲基环庚烷胺 | 495078-29-0

• 分子结构分类: 有机化合物 - 有机氮化合物
• 中文名称: 1-(氨甲基)-N,N-二甲基环庚烷胺
• 中文别名: N-[1-(氨基甲基)环庚基]-N,N-二甲胺
• 英文名称: 1-(aminomethyl)-N,N-dimethylcycloheptan-1-amine
• CAS: 495078-29-0
• 化学式: C₁₀H₂₂N₂
• mdl: MFCD05201531
• 分子量: 170.3
• InChiKey: UTXQTTHRHVLYSZ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.5
• 重原子数：
  12
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  29.3
• 氢给体数：
  1
• 氢受体数：
  2

安全信息

• 危险等级：
  IRRITANT
• 海关编码：
  2921300090

文献信息

• N-[(1-dimethylaminocycloalkyl)methyl]benzamide derivatives
  申请人：——

  公开号：US20040242685A1

  公开（公告）日：2004-12-02

  The present invention relates to N-[(1-dimethylaminocycloalkyl)methyl]benzamide derivatives having the general formula I 1 wherein n is 0, 1, 2 or 3; R 1 and R 2 are independently H, (C 1-4 )alkyl or (C 1-4 )alkyloxy; R 3 is (C 3-8 )alkyl, (C 4-7 )cycloalkyl, (C 4-7 )cycloalkyl (C 1-3 )alkyl, (C 6-12 )aryl(C 1-3 )alkyl (wherein the aryl moiety is optionally substituted with 1-3 substituents selected from (C 1-4 )alkyl, (C 1-4 )alkyloxy, halogen, trifluoromethyl and methoxycarbonyl), or (C 4-9 )heteroaryl(C 1-3 )alkyl; or a pharmaceutically acceptable salt thereof. The invention also relates to pharmaceutical compositions comprising said derivatives, and to the use of these N-[(1-dimethylaminocycloalkyl)methyl]benzamide derivatives in the treatment of disorders or conditions which are responsive to inhibition of the GlyT-2 transporter, such as muscle spasticity, epilepsy and, particularly, acute, chronic and neuropathic pain.

  本发明涉及具有一般式I1的N-［（1-二甲氨基环烷基）甲基］苯甲酰胺衍生物，其中n为0、1、2或3；R1和R2分别为H、（C1-4）烷基或（C1-4）烷氧基；R3为（C3-8）烷基、（C4-7）环烷基、（C4-7）环烷基（C1-3）烷基、（C6-12）芳基（C1-3）烷基（其中芳基基团可选地被1-3个取自（C1-4）烷基、（C1-4）烷氧基、卤素、三氟甲基和甲氧羰基的取代基所取代），或（C4-9）杂环芳基（C1-3）烷基；或其药学上可接受的盐。本发明还涉及包含所述衍生物的制药组合物，以及在治疗对GlyT-2转运体抑制有反应的疾病或病况，例如肌肉痉挛、癫痫和特别是急性、慢性和神经病理性疼痛中使用这些N-［（1-二甲氨基环烷基）甲基］苯甲酰胺衍生物的用途。
• N- (1-DIMETHYLAMINOCYCLOALKYL)METHYL]BENZAMIDE DERIVATIVES
  申请人：Akzo Nobel

  公开号：EP1419138A1

  公开（公告）日：2004-05-19
• N- (1-DIMETHYLAMINOCYCLOALKYL)METHYL BENZAMIDE DERIVATIVES
  申请人：N.V. Organon

  公开号：EP1419138B1

  公开（公告）日：2008-10-29
• US7126027B2
  申请人：——

  公开号：US7126027B2

  公开（公告）日：2006-10-24
• [EN] N-[(1-DIMETHYLAMINOCYCLOALKYL)METHYL]BENZAMIDE DERIVATIVES<br/>[FR] DÉRIVÉS DE N-[(1-DIMÉTHYLAMINOCYCLOALKYL)MÉTHYL]BENZAMIDE
  申请人：AKZO NOBEL NV

  公开号：WO2003010132A1

  公开（公告）日：2003-02-06

  The present invention relates to N-[(1-dimethylaminocycloalkyl)methyl]benzamide I derivatives having the general formula (I) wherein n is 0, 1, 2 or 3; R1 and R2 are independently H, (C1-4)alkyl or (C1-4)alkyloxy; R3 is (C3-8)alkyl, (C4-7)cycloalkyl, (C4-7)cycloalkyl (C1-3)alkyl, (C6-12)aryl(C1-3)alkyl (wherein the aryl moiety is optionailly substituted with 1-3 substituents selected from (C1-4)alkyl, (C1-4)alkyloxy, halogen, trifluoromethyl and methoxycarbonyl), or (C4-9)- heteroaryl(C1-3)alkyl; or a pharmaceutically acceptable salt thereof. The invention also relates to pharmaceutical compositions comprising said derivatives, and to the use of these N-[(1-dimethylaminocycloalkyl)methyl]benzamide derivatives in the treatment of disorders or conditions which are responsive to inhibition of the GlyT-2 transporter, such as muscle spasticity, epilepsy and, particularly, acute, chronic and neuropathic pain.